Substituted imidazoles as GLP-1 receptor agonists
The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt or tautomer thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and a compound of claim 1 , or a pharmaceutically acceptable salt or tautomer thereof.
3. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
4. The compound of claim 3 , which is:
5. The compound of claim 3 , which is a pharmaceutically acceptable salt of:
6. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and a compound of claim 3 , or a pharmaceutically acceptable salt or tautomer thereof.
7. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
8. The compound of claim 7 , which is:
9. The compound of claim 7 , which is a pharmaceutically acceptable salt of:
10. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 7 , or a pharmaceutically acceptable salt or tautomer thereof.
11. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
12. The compound of claim 11 , which is:
13. The compound of claim 11 , which is a pharmaceutically acceptable salt of:
14. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 11 , or a pharmaceutically acceptable salt or tautomer thereof.
15. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
16. The compound of claim 15 , which is:
17. The compound of claim 15 , which is a pharmaceutically acceptable salt of:
18. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 15 , or a pharmaceutically acceptable salt or tautomer thereof.
19. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
20. The compound of claim 19 , which is:
21. The compound of claim 19 , which is a pharmaceutically acceptable salt of:
22. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 19 , or a pharmaceutically acceptable salt or tautomer thereof.
23. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
24. The compound of claim 23 , which is:
25. The compound of claim 23 , which is a pharmaceutically acceptable salt of:
26. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 23 , or a pharmaceutically acceptable salt or tautomer thereof.
27. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
28. The compound of claim 27 , which is:
29. The compound of claim 27 , which is a pharmaceutically acceptable salt of:
30. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 27 , or a pharmaceutically acceptable salt or tautomer thereof.
31. A compound which is:
or a pharmaceutically acceptable salt or tautomer thereof.
32. The compound of claim 31 , which is:
33. The compound of claim 31 , which is a pharmaceutically acceptable salt of:
34. A pharmaceutical composition comprising a pharmaceutically acceptable diluent, carrier, or excipient and the compound of claim 31 , or a pharmaceutically acceptable salt or tautomer thereof.